Back to Journals » Stem Cells and Cloning: Advances and Applications » Volume 1

Defining the expression of marker genes in equine mesenchymal stromal cells

Authors Deborah J Guest, Jennifer C Ousey, Matthew RW Smith

Published 2 November 2008 Volume 2008:1 Pages 1—9

DOI https://doi.org/10.2147/SCCAA.S3824

Review by Single-blind

Peer reviewer comments 3

Deborah J Guest1, Jennifer C Ousey1, Matthew RW Smith2

1Animal Health Trust, Lanwades Park, Kentford, Newmarket, Suffolk, CB8 7UU; 2Reynolds House Referrals, Greenwood Ellis and Partners, 166 High Street, Newmarket, Suffolk, CB8 9WS, UK

Abstract: Mesenchymal stromal (MS) cells have been derived from multiple sources in the horse including bone marrow, adipose tissue and umbilical cord blood. To date these cells have been investigated for their differentiation potential and are currently being used to treat damage to horse musculoskeletal tissues. However, no work has been done in horse MS cells to examine the expression profile of proteins and cell surface antigens that are expressed in human MS cells. The identification of such profiles in the horse will allow the comparison of putative MS cells isolated from different laboratories and different tissues. At present it is difficult to ascertain whether equivalent cells are being used in different reports. Here, we report on the expression of a range of markers used to define human MS cells. Using immunocytochemistry we show that horse MS cells homogenously express collagens, alkaline phosphatase activity, CD44, CD90 and CD29. In contrast, CD14, CD79α and the embryonic stem cell markers Oct-4, SSEA (stage specific embryonic antigen) -1, -3, -4, TRA (tumor rejection antigen) -1–60 and -1–81 are not expressed. The MS cells also express MHC class I antigens but do not express class II antigens, although they are inducible by treatment with interferon gamma (IFN-γ).

Keywords: mesenchymal stem cells, equine, gene expression

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Mesenchymal stem cell therapy for osteoarthritis: current perspectives

Wyles CC, Houdek MT, Behfar A, Sierra RJ

Stem Cells and Cloning: Advances and Applications 2015, 8:117-124

Published Date: 28 August 2015

Engraftment of donor mesenchymal stem cells in chimeric BXSB includes vascular endothelial cells and hepatocytes

Jones OY, Gok F, Rushing EJ, Horkayne-Szakaly I, Ahmed AA

Stem Cells and Cloning: Advances and Applications 2011, 4:73-78

Published Date: 9 December 2011

Stem cell horizons in intervertebral disc degeneration

Joseph Ciacci, Allen Ho, Christopher P Ames, Rahul Jandial

Stem Cells and Cloning: Advances and Applications 2008, 1:31-39

Published Date: 20 January 2009

Stem cells and the origin of gliomas: A historical reappraisal with molecular advancements

Michael L Levy, Allen L Ho, Samuel Hughes, Jayant Menon, Rahul Jandial

Stem Cells and Cloning: Advances and Applications 2008, 1:41-47

Published Date: 20 January 2009